🇪🇺 Rituximab, Temsirolimus, DHAP, intravenous in European Union

EMA authorised Rituximab, Temsirolimus, DHAP, intravenous on 19 November 2007

Marketing authorisation

EMA — authorised 19 November 2007

• Application: EMEA/H/C/000799
• Marketing authorisation holder: Pfizer Europe MA EEIG
• Local brand name: Torisel
• Indication: Renal-cell carcinoma Torisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors. Mantle-cell lymphoma Torisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).
• Status: approved

Read official source →

Frequently asked questions

Is Rituximab, Temsirolimus, DHAP, intravenous approved in European Union?

Yes. EMA authorised it on 19 November 2007.

Who is the marketing authorisation holder for Rituximab, Temsirolimus, DHAP, intravenous in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.